KHAPZORY Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Khapzory, and when can generic versions of Khapzory launch?
Khapzory is a drug marketed by Acrotech Biopharma and is included in one NDA. There is one patent protecting this drug.
The generic ingredient in KHAPZORY is levoleucovorin. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the levoleucovorin profile page.
DrugPatentWatch® Generic Entry Outlook for Khapzory
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be March 25, 2039. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for KHAPZORY?
- What are the global sales for KHAPZORY?
- What is Average Wholesale Price for KHAPZORY?
Summary for KHAPZORY
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 22 |
| Patent Applications: | 1,490 |
| Drug Prices: | Drug price information for KHAPZORY |
| What excipients (inactive ingredients) are in KHAPZORY? | KHAPZORY excipients list |
| DailyMed Link: | KHAPZORY at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for KHAPZORY
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for KHAPZORY
| Drug Class | Folate Analog |
US Patents and Regulatory Information for KHAPZORY
KHAPZORY is protected by one US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of KHAPZORY is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting KHAPZORY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acrotech Biopharma | KHAPZORY | levoleucovorin | POWDER;INTRAVENOUS | 211226-001 | Oct 19, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Acrotech Biopharma | KHAPZORY | levoleucovorin | POWDER;INTRAVENOUS | 211226-002 | Oct 19, 2018 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
